VEGF111b, a new member of VEGFxxxb isoforms and induced by mitomycin C, inhibits angiogenesis
Journal Article
·
· Biochemical and Biophysical Research Communications
- Department of Obstetrics and Gynecology, Chinese PLA General Hospital, Beijing (China)
- Department of Hepatobiliary Surgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing (China)
- The Institute of Cardiovascular Sciences, Peking University Health Science Center, Key Laboratory of Molecular Cardiovascular Sciences of Education Ministry, Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides of Health Ministry, Beijing (China)
- Department of Obstetrics and Gynecology, Tangdu Hospital, Fourth Military Medical University, Xian (China)
Highlights: •We discovered a new member of VEGFxxxb family-VEGF111b. •We found VEGF111b mRNA and protein can be induced by mitomycin C. •We confirmed VEGF111b over-expression inhibits angiogenesis. •VEGF111b inhibits angiogenesis through inhibiting VEGF-R2/PI3K/Akt and VEGF-R2/ERK1/2 phosphorylation. -- Abstract: Vascular endothelial growth factor (VEGF-A) stimulating angiogenesis is required for tumor growth and progression. The conventional VEGF-A isoforms have been considered as pro-angiogenic factors. Another family of VEGF-A isoforms generated by alternative splicing, termed VEGFxxxb isoforms, has anti-angiogenic property, exemplified by VEGF165b. Here, we identify a new number of VEGFxxx family-VEGF111b induced by mitomycin C, although not detected in mitomycin C-unexposed ovarian cancer cells. SKOV3 cells were transfected with pcDNA{sub 3.1} empty vector, pcDNA{sub 3.1}-VEGF111b or pcDNA{sub 3.1}-VEGF165b to collect conditioned mediums respectively. VEGF111b overexpression inhibits proliferation, migration and tube formation of endothelial cell by inhibiting VEGF-R2 phosphorylation and its downstream signaling, similar to VEGF165b but slightly lower than VEGF165b. The anti-angiogenic property depends on the six amino acids of exon 8b of the VEGFxxxb isoforms. Our results show that VEGF111b is a novel potent anti-angiogenic agent that can target the VEGF-R2 and its signaling pathway to inhibit ovarian tumor growth.
- OSTI ID:
- 22242176
- Journal Information:
- Biochemical and Biophysical Research Communications, Journal Name: Biochemical and Biophysical Research Communications Journal Issue: 1 Vol. 441; ISSN BBRCA9; ISSN 0006-291X
- Country of Publication:
- United States
- Language:
- English
Similar Records
Increased expression of CYP4Z1 promotes tumor angiogenesis and growth in human breast cancer
Inhibition of VEGF-dependent angiogenesis by the anti-CD82 monoclonal antibody 4F9 through regulation of lipid raft microdomains
The tetrapeptide Arg-Leu-Tyr-Glu inhibits VEGF-induced angiogenesis
Journal Article
·
Mon Oct 01 00:00:00 EDT 2012
· Toxicology and Applied Pharmacology
·
OSTI ID:22215926
Inhibition of VEGF-dependent angiogenesis by the anti-CD82 monoclonal antibody 4F9 through regulation of lipid raft microdomains
Journal Article
·
Fri May 20 00:00:00 EDT 2016
· Biochemical and Biophysical Research Communications
·
OSTI ID:22598733
The tetrapeptide Arg-Leu-Tyr-Glu inhibits VEGF-induced angiogenesis
Journal Article
·
Fri Aug 07 00:00:00 EDT 2015
· Biochemical and Biophysical Research Communications
·
OSTI ID:22462134